The Effects of Modulating Chronic Low Grade Inflammation on Geriatric Conditions: Secondary Data and/or Biospecimen Analyses and Ancillary Studies in Ongoing or Completed Clinical Trials (R01)

The summary for the The Effects of Modulating Chronic Low Grade Inflammation on Geriatric Conditions: Secondary Data and/or Biospecimen Analyses and Ancillary Studies in Ongoing or Completed Clinical Trials (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

The Effects of Modulating Chronic Low Grade Inflammation on Geriatric Conditions: Secondary Data and/or Biospecimen Analyses and Ancillary Studies in Ongoing or Completed Clinical Trials (R01): The purpose of this Funding Opportunity Announcement (FOA) is to invite applications to perform ancillary studies and secondary analyses of data and/or biospecimens from ongoing or completed studies of the effects of inflammation and/or anti-inflammatory agents on geriatric conditions, such as functional decline, mobility disability, fatigue, falls, cognitive decline/dementia, and chronic pain. Data that can inform designs of possible future interventional studies on modulating the effects of chronic inflammation in such conditions are of particular interest. Analyses of both beneficial and harmful effects of modulating chronic inflammation in older individuals are of interest. Other types of studies of interest to NIA include mechanistic studies to explore the pathophysiologic processes by which chronic, low-grade inflammation may accelerate functional decline or other geriatric conditions, and how these pathways may be disrupted by interventions. The secondary analyses and ancillary studies supported by this (FOA) may be based on data and/or biospecimens from either ongoing or completed clinical trials.

Federal Grant Title:	The Effects of Modulating Chronic Low Grade Inflammation on Geriatric Conditions: Secondary Data and/or Biospecimen Analyses and Ancillary Studies in Ongoing or Completed Clinical Trials (R01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PA-13-221
Type of Funding:	Grant
CFDA Numbers:	93.866
CFDA Descriptions:	Aging Research
Current Application Deadline:	Sep 07, 2016
Original Application Deadline:	Sep 07, 2016
Posted Date:	May 03, 2013
Creation Date:	May 03, 2013
Archive Date:	Oct 08, 2016
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Nathan Shock Centers Coordinating Center (U24 Clinical Trial Not Allowed); • Nathan Shock Centers of Excellence in Basic Biology of Aging (P30 Clinical Trial Not Allow...; • Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (...; • Exploring Proteogenomic Approaches to Unravel the Mechanisms of Mis-Folded Protein Accumul...; • Research Training in Aging for Medical Students (T35); • Technological Enhancements and Archiving for Surveys of the Elderly: SBIR (R43/44) Initiat...; • Technological Enhancements and Archiving for Surveys of the Elderly: STTR (R41/42) Initiat...; • Technology and Aging: NIA Small Business Technology Transfer Program Initiative (STTR [R41...
More Grants from the National Institutes of Health: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...